152 related articles for article (PubMed ID: 33652058)
1. Emerging roles of dehydrogenase/reductase member 2 (DHRS2) in the pathology of disease.
Li Z; Liu H; Bode A; Luo X
Eur J Pharmacol; 2021 May; 898():173972. PubMed ID: 33652058
[TBL] [Abstract][Full Text] [Related]
2. DHRS2 mediates cell growth inhibition induced by Trichothecin in nasopharyngeal carcinoma.
Luo X; Li N; Zhao X; Liao C; Ye R; Cheng C; Xu Z; Quan J; Liu J; Cao Y
J Exp Clin Cancer Res; 2019 Jul; 38(1):300. PubMed ID: 31291971
[TBL] [Abstract][Full Text] [Related]
3. DHRS2 inhibits cell growth and metastasis in ovarian cancer by downregulation of CHKα to disrupt choline metabolism.
Li Z; Tan Y; Li X; Quan J; Bode AM; Cao Y; Luo X
Cell Death Dis; 2022 Oct; 13(10):845. PubMed ID: 36192391
[TBL] [Abstract][Full Text] [Related]
4. Dehydrogenase/reductase SDR family member 2 silencing sensitizes an oxaliplatin‑resistant cell line to oxaliplatin by inhibiting excision repair cross‑complementing group 1 protein expression.
Li JM; Jiang GM; Zhao L; Yang F; Yuan WQ; Wang H; Luo YQ
Oncol Rep; 2019 Nov; 42(5):1725-1734. PubMed ID: 31436301
[TBL] [Abstract][Full Text] [Related]
5. Decreased DHRS2 expression is associated with HDACi resistance and poor prognosis in ovarian cancer.
Han Y; Wang Z; Sun S; Zhang Z; Liu J; Jin X; Wu P; Ji T; Ding W; Wang B; Gao Q
Epigenetics; 2020; 15(1-2):122-133. PubMed ID: 31423895
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the dehydrogenase-reductase DHRS2 and its involvement in histone deacetylase inhibition in urological malignancies.
Müller MR; Burmeister A; Skowron MA; Stephan A; Söhngen C; Wollnitzke P; Petzsch P; Alves Avelar LA; Kurz T; Köhrer K; Levkau B; Nettersheim D
Exp Cell Res; 2024 May; 439(1):114055. PubMed ID: 38704080
[TBL] [Abstract][Full Text] [Related]
7. Deciphering the molecular effects of romidepsin on germ cell tumours: DHRS2 is involved in cell cycle arrest but not apoptosis or induction of romidepsin effectors.
Nettersheim D; Berger D; Jostes S; Skowron M; Schorle H
J Cell Mol Med; 2019 Jan; 23(1):670-679. PubMed ID: 30460772
[TBL] [Abstract][Full Text] [Related]
8. DHRS2 inhibits cell growth and motility in esophageal squamous cell carcinoma.
Zhou Y; Wang L; Ban X; Zeng T; Zhu Y; Li M; Guan XY; Li Y
Oncogene; 2018 Feb; 37(8):1086-1094. PubMed ID: 29106393
[TBL] [Abstract][Full Text] [Related]
9. Crystal structure and catalytic characterization of the dehydrogenase/reductase SDR family member 4 (DHRS4) from Caenorhabditis elegans.
Kisiela M; Faust A; Ebert B; Maser E; Scheidig AJ
FEBS J; 2018 Jan; 285(2):275-293. PubMed ID: 29151266
[TBL] [Abstract][Full Text] [Related]
10. Bioinformatic and biochemical characterization of DCXR and DHRS2/4 from Caenorhabditis elegans.
Kisiela M; El-Hawari Y; Martin HJ; Maser E
Chem Biol Interact; 2011 May; 191(1-3):75-82. PubMed ID: 21300042
[TBL] [Abstract][Full Text] [Related]
11. Reductase enzyme expression across the National Cancer Institute Tumor cell line panel: correlation with sensitivity to mitomycin C and EO9.
Fitzsimmons SA; Workman P; Grever M; Paull K; Camalier R; Lewis AD
J Natl Cancer Inst; 1996 Mar; 88(5):259-69. PubMed ID: 8614004
[TBL] [Abstract][Full Text] [Related]
12. Synergistic anticancer activity of doxorubicin and piperlongumine on DU-145 prostate cancer cells - The involvement of carbonyl reductase 1 inhibition.
Piska K; Koczurkiewicz P; Wnuk D; Karnas E; Bucki A; Wójcik-Pszczoła K; Jamrozik M; Michalik M; Kołaczkowski M; Pękala E
Chem Biol Interact; 2019 Feb; 300():40-48. PubMed ID: 30611789
[TBL] [Abstract][Full Text] [Related]
13. Auxiliary Diagnosis and Prognostic Value of Dehydrogenase/Reductase 2 (DHRS2) in Various Tumors.
An Z; Bo W; Qin J; Jiang L; Jiang J
Iran J Public Health; 2023 Jun; 52(6):1150-1160. PubMed ID: 37484140
[TBL] [Abstract][Full Text] [Related]
14. Crystal structure of the ternary complex of mouse lung carbonyl reductase at 1.8 A resolution: the structural origin of coenzyme specificity in the short-chain dehydrogenase/reductase family.
Tanaka N; Nonaka T; Nakanishi M; Deyashiki Y; Hara A; Mitsui Y
Structure; 1996 Jan; 4(1):33-45. PubMed ID: 8805511
[TBL] [Abstract][Full Text] [Related]
15. Targeting cancer metabolism to develop human lactate dehydrogenase (hLDH)5 inhibitors.
Zhang SL; He Y; Tam KY
Drug Discov Today; 2018 Jul; 23(7):1407-1415. PubMed ID: 29750903
[TBL] [Abstract][Full Text] [Related]
16. Aldo-Keto Reductase Family 1 Member B10 Inhibitors: Potential Drugs for Cancer Treatment.
Huang L; He R; Luo W; Zhu YS; Li J; Tan T; Zhang X; Hu Z; Luo D
Recent Pat Anticancer Drug Discov; 2016; 11(2):184-96. PubMed ID: 26844556
[TBL] [Abstract][Full Text] [Related]
17. Molecular and functional evolution of human DHRS2 and DHRS4 duplicated genes.
Gabrielli F; Tofanelli S
Gene; 2012 Dec; 511(2):461-9. PubMed ID: 23036705
[TBL] [Abstract][Full Text] [Related]
18. Identification and Characterization of a Selective Human Carbonyl Reductase 1 Substrate.
Ramsden D; Smith D; Arenas R; Frederick K; Cerny MA
Drug Metab Dispos; 2018 Oct; 46(10):1434-1440. PubMed ID: 30068520
[TBL] [Abstract][Full Text] [Related]
19. Biochemical properties of human dehydrogenase/reductase (SDR family) member 7.
Stambergova H; Skarydova L; Dunford JE; Wsol V
Chem Biol Interact; 2014 Jan; 207():52-7. PubMed ID: 24246760
[TBL] [Abstract][Full Text] [Related]
20. Nicotinamide, a glucose-6-phosphate dehydrogenase non-competitive mixed inhibitor, modifies redox balance and lipid accumulation in 3T3-L1 cells.
Torres-Ramírez N; Baiza-Gutman LA; García-Macedo R; Ortega-Camarillo C; Contreras-Ramos A; Medina-Navarro R; Cruz M; Ibáñez-Hernández MÁ; Díaz-Flores M
Life Sci; 2013 Dec; 93(25-26):975-85. PubMed ID: 24184296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
